What is iQure Pharma?
iQure Pharma operates at the intersection of neurology and drug discovery, specializing in the development of innovative therapies for central nervous system (CNS) disorders. The company's core mission revolves around restoring glutamate homeostasis, a critical biological process often disrupted in neurodegenerative conditions and chronic pain. Its flagship asset, iQ-007, represents a first-in-class small molecule currently undergoing Phase 1 clinical trials for treatment-resistant epilepsy. By targeting the primary glutamate transporter, the firm aims to mitigate neuronal damage caused by excitotoxicity. This scientific approach is bolstered by partnerships with leading academic and research institutions, ensuring that their therapeutic pipeline remains grounded in rigorous, evidence-based validation.
How much funding has iQure Pharma raised?
iQure Pharma has raised a total of $2.5M across 3 funding rounds:
Series A
$600K
Other Financing Round
$1.2M
Private Equity
$650K
Series A (2022): $600K with participation from Keiretsu Forum Mid-Atlantic
Other Financing Round (2023): $1.2M, investors not publicly disclosed
Private Equity (2026): $650K, investors not publicly disclosed
Key Investors in iQure Pharma
Keiretsu Forum Mid-Atlantic
A prominent angel investor network that provides early-stage capital and due diligence support to emerging growth businesses.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for iQure Pharma?
With the recent capital infusion, iQure Pharma is well-positioned to transition from early-stage development to more robust clinical validation. The strategic roadmap likely involves expanding the Phase 1 trials for iQ-007 and potentially initiating preclinical studies for secondary pipeline candidates. As the company navigates the regulatory landscape, the focus will remain on demonstrating the efficacy of its glutamate-modulating platform. Investors and industry observers will be closely monitoring the company's ability to translate its laboratory successes into tangible clinical outcomes, which will be essential for future valuation growth and potential commercialization partnerships in the competitive CNS therapeutic space.
See full iQure Pharma company page
